During the visit of Industry Counselor Mikel Irujo, Lozys Pharma’s detailed €5 million investment plan was unveiled, strategically focusing on the consolidation, digitalization, and energy efficiency of its operations. The impressive results of the year 2023 have been revealed, with a remarkable growth of 22%, reaching the production of 17 million units of lozenges. 

As an integral part of the Qube Pharma Group, Lozys Pharma plays a crucial role in driving economic development and local employment. We emphasize the importance of decisive support from the Government of Navarra in this process, support that has been instrumental in achieving these significant accomplishments. 

From Geiser Pharma, a member of the Qube Group and in close collaboration with Lozys Pharma, we are pleased to share this exciting news. At Geiser Pharma, we stand out for our specialization in the development of high-value pharmaceutical products, covering key areas of the sector. We implement advanced technologies and innovative pharmaceutical forms to provide cutting-edge and effective solutions. 

The prospect of a promising future fills us with excitement, and we continue to work tirelessly to establish ourselves as leaders in innovation, contributing significantly to the advancement of global health. Our commitment to business growth in Navarra is strengthened as we grow together, reinforcing the excellence of the Qube Pharma Group. 

We are grateful for the opportunity to share these exceptional achievements and look forward to exciting developments in our ongoing pursuit of excellence.